Cargando…

Blockade Antibody Responses in Human Subjects Challenged with a New Snow Mountain Virus Inoculum

BACKGROUND: Noroviruses (NoVs) are a leading cause of non-bacterial gastroenteritis in young children and adults worldwide. Snow Mountain Virus (SMV) is the prototype of NoV GII genotype 2 (GII.2) that has been developed as a viral model for human challenge models, an important tool for studying pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibaraki, Makoto, Lai, Lilin, Huerta, Christopher, Natrajan, Muktha S., Collins, Matthew H., Anderson, Evan J., Mulligan, Mark J., Rouphael, Nadine, Moe, Christine L., Liu, Pengbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543019/
https://www.ncbi.nlm.nih.gov/pubmed/37790500
http://dx.doi.org/10.21203/rs.3.rs-3153900/v1
_version_ 1785114209194868736
author Ibaraki, Makoto
Lai, Lilin
Huerta, Christopher
Natrajan, Muktha S.
Collins, Matthew H.
Anderson, Evan J.
Mulligan, Mark J.
Rouphael, Nadine
Moe, Christine L.
Liu, Pengbo
author_facet Ibaraki, Makoto
Lai, Lilin
Huerta, Christopher
Natrajan, Muktha S.
Collins, Matthew H.
Anderson, Evan J.
Mulligan, Mark J.
Rouphael, Nadine
Moe, Christine L.
Liu, Pengbo
author_sort Ibaraki, Makoto
collection PubMed
description BACKGROUND: Noroviruses (NoVs) are a leading cause of non-bacterial gastroenteritis in young children and adults worldwide. Snow Mountain Virus (SMV) is the prototype of NoV GII genotype 2 (GII.2) that has been developed as a viral model for human challenge models, an important tool for studying pathogenesis and immune response of NoV infections and for evaluating NoV vaccine candidates. Previous studies have identified blockade antibodies that block the binding of NoV virus-like particles (VLPs) to histo-blood group antigens (HBGAs) as a surrogate for neutralization in human Norwalk virus and GII.4 infections but little is known about SMV blockade antibodies. METHODS: In this secondary data analysis study, blockade antibodies were characterized in pre-challenge and post-challenge serum samples from human subjects challenged with a new SMV inoculum. The correlation between blockade antibody geometric mean antibody titers (GMTs) and SMV-specific serum IgG/IgA GMTs were examined after stratifying the subjects by infection status. A linear mixed model was applied to test the association between HBGA blockade antibody concentrations and post-challenge days accounting for covariates and random effects. RESULTS: Laboratory results from 33 SMV inoculated individuals were analyzed and 75.7% (25/33) participants became infected. Serum SMV-specific blockade antibodies, IgA, and IgG were all significantly different between infected and uninfected individuals beginning day 15 post-challenge. Within infected individuals, a significant correlation was observed between both IgG and IgA and blockade antibody concentration as early as day 6 post-challenge. Analysis of blockade antibody using the linear mixed model showed that infected individuals, when compared to uninfected individuals, had a statistically significant increase in blockade antibody concentrations across the post-challenge days. Among the post-challenge days, blockade antibody concentrations on days 15, 30, and 45 were significantly higher than those observed pre-challenge. The intraclass correlation coefficient (ICC) analysis indicated that the variability of blockade antibody titers is more observed between individuals rather than observations within subjects. CONCLUSIONS: These results indicate that HBGA-blockade antibody GMTs are generated after SMV challenge and the blockade antibodies were still detectable at day 45 post-challenge. These data indicate that the second generation of SMV inoculum is highly effective.
format Online
Article
Text
id pubmed-10543019
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Journal Experts
record_format MEDLINE/PubMed
spelling pubmed-105430192023-10-03 Blockade Antibody Responses in Human Subjects Challenged with a New Snow Mountain Virus Inoculum Ibaraki, Makoto Lai, Lilin Huerta, Christopher Natrajan, Muktha S. Collins, Matthew H. Anderson, Evan J. Mulligan, Mark J. Rouphael, Nadine Moe, Christine L. Liu, Pengbo Res Sq Article BACKGROUND: Noroviruses (NoVs) are a leading cause of non-bacterial gastroenteritis in young children and adults worldwide. Snow Mountain Virus (SMV) is the prototype of NoV GII genotype 2 (GII.2) that has been developed as a viral model for human challenge models, an important tool for studying pathogenesis and immune response of NoV infections and for evaluating NoV vaccine candidates. Previous studies have identified blockade antibodies that block the binding of NoV virus-like particles (VLPs) to histo-blood group antigens (HBGAs) as a surrogate for neutralization in human Norwalk virus and GII.4 infections but little is known about SMV blockade antibodies. METHODS: In this secondary data analysis study, blockade antibodies were characterized in pre-challenge and post-challenge serum samples from human subjects challenged with a new SMV inoculum. The correlation between blockade antibody geometric mean antibody titers (GMTs) and SMV-specific serum IgG/IgA GMTs were examined after stratifying the subjects by infection status. A linear mixed model was applied to test the association between HBGA blockade antibody concentrations and post-challenge days accounting for covariates and random effects. RESULTS: Laboratory results from 33 SMV inoculated individuals were analyzed and 75.7% (25/33) participants became infected. Serum SMV-specific blockade antibodies, IgA, and IgG were all significantly different between infected and uninfected individuals beginning day 15 post-challenge. Within infected individuals, a significant correlation was observed between both IgG and IgA and blockade antibody concentration as early as day 6 post-challenge. Analysis of blockade antibody using the linear mixed model showed that infected individuals, when compared to uninfected individuals, had a statistically significant increase in blockade antibody concentrations across the post-challenge days. Among the post-challenge days, blockade antibody concentrations on days 15, 30, and 45 were significantly higher than those observed pre-challenge. The intraclass correlation coefficient (ICC) analysis indicated that the variability of blockade antibody titers is more observed between individuals rather than observations within subjects. CONCLUSIONS: These results indicate that HBGA-blockade antibody GMTs are generated after SMV challenge and the blockade antibodies were still detectable at day 45 post-challenge. These data indicate that the second generation of SMV inoculum is highly effective. American Journal Experts 2023-09-11 /pmc/articles/PMC10543019/ /pubmed/37790500 http://dx.doi.org/10.21203/rs.3.rs-3153900/v1 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Article
Ibaraki, Makoto
Lai, Lilin
Huerta, Christopher
Natrajan, Muktha S.
Collins, Matthew H.
Anderson, Evan J.
Mulligan, Mark J.
Rouphael, Nadine
Moe, Christine L.
Liu, Pengbo
Blockade Antibody Responses in Human Subjects Challenged with a New Snow Mountain Virus Inoculum
title Blockade Antibody Responses in Human Subjects Challenged with a New Snow Mountain Virus Inoculum
title_full Blockade Antibody Responses in Human Subjects Challenged with a New Snow Mountain Virus Inoculum
title_fullStr Blockade Antibody Responses in Human Subjects Challenged with a New Snow Mountain Virus Inoculum
title_full_unstemmed Blockade Antibody Responses in Human Subjects Challenged with a New Snow Mountain Virus Inoculum
title_short Blockade Antibody Responses in Human Subjects Challenged with a New Snow Mountain Virus Inoculum
title_sort blockade antibody responses in human subjects challenged with a new snow mountain virus inoculum
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543019/
https://www.ncbi.nlm.nih.gov/pubmed/37790500
http://dx.doi.org/10.21203/rs.3.rs-3153900/v1
work_keys_str_mv AT ibarakimakoto blockadeantibodyresponsesinhumansubjectschallengedwithanewsnowmountainvirusinoculum
AT laililin blockadeantibodyresponsesinhumansubjectschallengedwithanewsnowmountainvirusinoculum
AT huertachristopher blockadeantibodyresponsesinhumansubjectschallengedwithanewsnowmountainvirusinoculum
AT natrajanmukthas blockadeantibodyresponsesinhumansubjectschallengedwithanewsnowmountainvirusinoculum
AT collinsmatthewh blockadeantibodyresponsesinhumansubjectschallengedwithanewsnowmountainvirusinoculum
AT andersonevanj blockadeantibodyresponsesinhumansubjectschallengedwithanewsnowmountainvirusinoculum
AT mulliganmarkj blockadeantibodyresponsesinhumansubjectschallengedwithanewsnowmountainvirusinoculum
AT rouphaelnadine blockadeantibodyresponsesinhumansubjectschallengedwithanewsnowmountainvirusinoculum
AT moechristinel blockadeantibodyresponsesinhumansubjectschallengedwithanewsnowmountainvirusinoculum
AT liupengbo blockadeantibodyresponsesinhumansubjectschallengedwithanewsnowmountainvirusinoculum